Differences between myeloperoxidase-antineutrophil cytoplasmic autoantibody (ANCA) and proteinase 3-ANCA associated vasculitis: A retrospective study from a single center in China

Abstract

In antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitides (AAV), the two major target antigens of ANCA are proteinase 3 (PR3) and myeloperoxidase (MPO). Evidence is accumulating that there are distinct differences between patients with PR3-AAV and those with MPO-AAV. In the present study, the clinicopathological features and prognosis of patients with PR3-AAV and MPO-AAV from a single center in China were retrospectively analyzed. A total of 212 Chinese patients with AAV were recruited in the present study; 189/212 (89.15%) patients were classified as having MPO-AAV and 23/212 (10.85%) patients as having PR3-AAV. Compared with those in the PR3-AAV group, patients in the MPO-AAV group were older and less frequently had ear, nose and throat or ophthalmic involvement. MPO-AAV patients had higher levels of serum creatinine and proteinuria at baseline. No significant difference was observed with regard to the pathological changes of the glomeruli and tubulointerstitium between the two groups. The probability of developing end-stage renal disease was significantly higher in patients with MPO-AAV compared with that in patients with PR3-AAV. There was no significant difference in the one-year patient survival rate between the two groups. However, differences in certain clinical characteristics and outcomes were observed between MPO-AAV and PR3-AAV patients. A large national investigation of AAV is required to confirm the concept that PR3-AAV and MPO-AAV are distinct disease entities.

Keywords: antineutrophil cytoplasmic autoantibody; clinicopathological features; myeloperoxidase; prognosis; proteinase 3.

Figure 1

Renal survival of patients with different types of AAV. Follow-up time (months) refers to the time since the start of treatment. AAV, antineutrophil cytoplasmic autoantibody-associated vasculitides; PR3, proteinase 3; MPO, myeloperoxidase.

Figure 2

Patient survival of cases with different types of AAV. Follow-up time (months) refers to the time since the start of treatment. AAV, antineutrophil cytoplasmic autoantibody-associated vasculitides; PR3, proteinase 3; MPO, myeloperoxidase.